NCT02964702已完成不适用
A Multicenter, Single-arm Study of the Efficacy and Safety of a Thrombectomy Device (T-01) for the Treatment of Acute Cerebral Infarction
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 13
- 主要终点
- The primary efficacy endpoint of the study is rate of immediate post-procedure reperfusion with the device in 2 pathways/device or 3 pathways/vessel measured using Thrombolysis in Cerebrovascular Infarction (TICI) score of 2a or greater.
研究概览
简要总结
To evaluate the efficacy and safety of catheter-based thrombectomy for reperfusion by removing a thrombus in a cerebral blood vessel in patients with acute cerebral infarction (within 8 hours after onset), in whom intravenous administration of tissue plasminogen activator (t-PA) is not indicated or reperfusion cannot be achieved by intravenous t-PA administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with neurological disorders caused by blood vessel occlusion associated with acute cerebral infarction
- •Patients who can receive treatment within 8 hours after onset of symptoms of acute cerebral infarction
- •Patients in whom intravenous administration of t-PA is not indicated or reperfusion cannot be achieved by intravenous t-PA administration
- •Patients who have accessible occlusion of the middle cerebral artery (M1 or M2 to 3), basilar artery, vertebral artery, posterior cerebral artery (P1 or P2), anterior cerebral artery (A1 to 2), or intracranial internal carotid artery (pre-procedure TICI score, 0 or 1) as determined by angiography
- •Patients with an NIHSS score of 8 to 30
- •Patients with an mRS score of 0 to 2 before onset
- •Patients aged between 20 and 85 years (at the time of informed consent)
- •Patients who are able to provide written consent (signature) or whose legally acceptable representative (a person with parental authority, spouse, guardian, and an individual legally responsible for his/her custody) can provide written consent (signature)
排除标准
- •Patients who manifest the following:
- •Carotid artery dissection
- •Vasculitis
- •An angulated vessel, making it difficult to guide an investigational device
- •Significant (>50%) stenosis, making it difficult to guide an investigational device
- •Acute intracranial hemorrhage
- •Mass lesion or intracranial tumor
- •Widespread early ischemic changes revealed by CT or MRI
- •Patients who have two or more different major cerebrovascular occlusions requiring treatment
- •Patients with an allergy to contrast agents or who cannot receive them or those who have a serious metal allergy
- •Patients who received heparin within 48 hours and have Partial Thromboplastin Time (PTT)/Activated Partial Thromboplastin Time (APTT) > twice the upper limit of normal
- •Patients with known bleeding tendencies or coagulation deficiency or who have received oral anticoagulants (such as warfarin), and who have (PT-) International Normalized Ratio (INR) >3
- •Patients with platelet count <30,000 /mm3
- •Patients with blood glucose levels <50 mg/dL
- •Patients with uncontrolled hypertension (systolic BP >185 mmHg and diastolic BP >110 mmHg)
- •Patients with expected life expectancy <90 days
- •Female patients who are pregnant or breast feeding
- •Patients who are participating in clinical trials of drugs or medical devices
- •Patients disqualified from participation in the study by the investigator (sub-investigator) due to reasons other than the above
研究组 & 干预措施
Thrombectomy Device(T-01)
Experimental
Mechanical Thrombectomy with T-01
干预措施: Thrombectomy Device T-01 (Device)
结局指标
主要结局
The primary efficacy endpoint of the study is rate of immediate post-procedure reperfusion with the device in 2 pathways/device or 3 pathways/vessel measured using Thrombolysis in Cerebrovascular Infarction (TICI) score of 2a or greater.
时间窗: immediate post procedure
The primary safety endpoint of the study is mortality within 90 days after the procedure
时间窗: 90 days
次要结局
- Rate of reperfusion not accompanied by symptomatic intracranial hemorrhage within 24 hours after the procedure(24 hours)
- Incidence of symptomatic intracranial hemorrhage within 24 hours after the procedure(24 hours)
- Proportion of subjects with newly diagnosed embolism accompanied by immediate post-procedure embolectomy(immediate post-procedure)
- Proportion of subjects who have modified Rankin Scale (mRS) score of 2 or greater whose National Institute of Health Stroke Scale (NIHSS) score improved by 10 points or more from baseline at 90 days post-procedure(90 days)
- Assessment of mRS scores at 90 days post-procedure(90 days)
- Assessment of NIHSS scores at 90 days post-procedure(90 days)
- Assessment of Barthel Index (BI) scores at 90 days post-procedure(90 days)
- Incidence of intracranial hemorrhage including both symptomatic and asymptomatic within 24 hours after the procedure(24 hours)
- Incidence of asymptomatic intracranial hemorrhage within 24 hours after the procedure(24 hours)
- Incidence of device- or procedure-related serious adverse events within 90 days after the procedure(90 days)
- Number of any defect in the investigational device(at the time of inspection before procedure, intraoperative and immediate post-procedure)
研究者
研究点 (13)
Loading locations...
相似试验
已完成
不适用
A Study to Evaluate the Q Revascularization System for Neurointervention in Acute Ischemic StrokeAcute StrokeCerebral IschemiaNCT04437862MIVI Neuroscience, Inc.121
进行中（未招募）
不适用
NATURE (EnVast as an Adjunct PPCI in Subjects Presenting With STEMI)Segment Elevation Myocardial Infarction (STEMI)NCT04969471Vesalio148
招募中
不适用
Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel CatheterAcute Ischemic Stroke From Large Vessel OcclusionNCT06370182Anaconda Biomed S.L.327
暂停
不适用
Safety and Effectiveness of the Akura Thrombectomy System for Use in the Removal of Emboli From the Pulmonary Arteries in Treating Acute Pulmonary Embolism (PE)NCT06672510Akura Medical118
撤回
不适用
Safety and Effectiveness of the Akura Thrombectomy System in the Treatment of Acute Pulmonary EmbolismPulmonary Embolism AcuteNCT06362928Akura Medical15